View
213
Download
0
Category
Preview:
Citation preview
Grupo Español de Cáncer de Pulmón
Spanish Lung Cancer Group
Av. Meridiana, 358 6ª planta 08027 BarcelonaTel.: + 34 934 302 006 secretaria@gecp.org www.gecp.org
www.gecp.org
Inscripción abierta. Plazas limitadas.
NEWSLETTER / Enero 18
Concurso musical No dejes que el tabaco entre en tu vida:cantando contra el tabaco”
“
►
►
►
►
►
►
►
-
-
-
-
Stage IIIB-IV NSCLC
Confirmed EGFRm
Confirmed T790M
PD on/after previous EGFR TKI
1 : 1
Bevacizumab 15mg/kg i.v.
day 1 of each 3-week cycle
Osimertinib 80mg p.o. daily
∙∙∙
∙∙∙
∙∙∙
until progression*, lack of
tolerability or refusal
until progression*, lack of
tolerability or refusal
Osimertinib 80mg p.o. daily
R
* Trial treatment may continue beyond
progression if the patient shows
clinical benefit
CTCT
3Weeks 6 9 18 270
Blood
FFPE
BloodBlood
CT CT CT
(FFPE)
at
progression
Biomaterial
collection:
T
-
-
-
-
-
-
-
-
-
-
-
- Rosell R. et al Lancet Respiratory Medicine Volume 5, No. 5, p 435-444http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(17)30129-7/fulltext
-
-
Recommended